HighTide Therapeutics (HIGHTIDE-B) Maintains Stable Share Base and Meets HKEX Public-Float Rule in May 2026

Bulletin Express

Jun 01

HighTide Therapeutics, Inc., a Cayman-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, reported no changes in either its authorised or issued share capital for the month ended 31 May 2026.

• Authorised share capital: Remained at 1.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 0.10 million.

• Issued shares: Unchanged at 571.33 million ordinary shares; the company held no treasury shares, and there were no share repurchases or cancellations during the month.

• Capital-raising instruments: The issuer reported no activity under share option schemes, warrants, convertible securities, or other equity-related agreements.

• Public float: Management confirmed compliance with the Main Board’s minimum 25% float requirement as of 31 May 2026.

The monthly return was signed by Executive Director and CEO Dr. Liu Liping and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184289205"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184289205\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184289205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184289205","market":"hk","top_or_hot":-1,"title":"HighTide Therapeutics (HIGHTIDE-B) Maintains Stable Share Base and Meets HKEX Public-Float Rule in May 2026","media":"Bulletin Express","content":"<p>HighTide Therapeutics, Inc., a Cayman-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, reported no changes in either its authorised or issued share capital for the month ended 31 May 2026.</p>\n<p>• Authorised share capital: Remained at 1.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 0.10 million.</p>\n<p>• Issued shares: Unchanged at 571.33 million ordinary shares; the company held no treasury shares, and there were no share repurchases or cancellations during the month.</p>\n<p>• Capital-raising instruments: The issuer reported no activity under share option schemes, warrants, convertible securities, or other equity-related agreements.</p>\n<p>• Public float: Management confirmed compliance with the Main Board’s minimum 25% float requirement as of 31 May 2026.</p>\n<p>The monthly return was signed by Executive Director and CEO Dr. Liu Liping and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics (HIGHTIDE-B) Maintains Stable Share Base and Meets HKEX Public-Float Rule in May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics (HIGHTIDE-B) Maintains Stable Share Base and Meets HKEX Public-Float Rule in May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 16:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HighTide Therapeutics, Inc., a Cayman-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, reported no changes in either its authorised or issued share capital for the month ended 31 May 2026.</p>\n<p>• Authorised share capital: Remained at 1.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 0.10 million.</p>\n<p>• Issued shares: Unchanged at 571.33 million ordinary shares; the company held no treasury shares, and there were no share repurchases or cancellations during the month.</p>\n<p>• Capital-raising instruments: The issuer reported no activity under share option schemes, warrants, convertible securities, or other equity-related agreements.</p>\n<p>• Public float: Management confirmed compliance with the Main Board’s minimum 25% float requirement as of 31 May 2026.</p>\n<p>The monthly return was signed by Executive Director and CEO Dr. Liu Liping and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"","article_id":"1184289205","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184289205","pubTimestamp":1780303731,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HighTide Therapeutics, Inc., a Cayman-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, reported no changes in either its authorised or issued share capital for the month...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B"},"translate_title":"HighTide Therapeutics(HIGHTIDE-B)保持稳定的股份基础并于2026年5月满足香港交易所公众持股量规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":1},"content_text":"HighTide Therapeutics, Inc., a Cayman-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, reported no changes in either its authorised or issued share capital for the month ended 31 May 2026.\n• Authorised share capital: Remained at 1.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 0.10 million.\n• Issued shares: Unchanged at 571.33 million ordinary shares; the company held no treasury shares, and there were no share repurchases or cancellations during the month.\n• Capital-raising instruments: The issuer reported no activity under share option schemes, warrants, convertible securities, or other equity-related agreements.\n• Public float: Management confirmed compliance with the Main Board’s minimum 25% float requirement as of 31 May 2026.\nThe monthly return was signed by Executive Director and CEO Dr. Liu Liping and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}